Mangaciclanol’s Phase I trial showed it was well tolerated, with no serious adverse events or clinically significant findings ...
GE HealthCare has received FDA clearance for three new SIGNA MRI innovations aimed at improving efficiency, diagnostic accuracy, and sustainability. The systems integrate AI-enabled workflows and ...
Zacks Investment Research on MSN
GEHC moves manganese-based MRI contrast agent into phase 2/3 trial
GE HealthCare Technologies Inc. GEHC recently announced that the first patient has been dosed in its Phase 2/3 LUMINA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results